Your browser doesn't support javascript.
loading
The prognostic value of serum C-reactive protein, ferritin, and albumin prior to allogeneic transplantation for acute myeloid leukemia and myelodysplastic syndromes.
Artz, Andrew S; Logan, Brent; Zhu, Xiaochun; Akpek, Gorgun; Bufarull, Rodrigo Martino; Gupta, Vikas; Lazarus, Hillard M; Litzow, Mark; Loren, Alison; Majhail, Navneet S; Maziarz, Richard T; McCarthy, Philip; Popat, Uday; Saber, Wael; Spellman, Stephen; Ringden, Olle; Wickrema, Amittha; Pasquini, Marcelo C; Cooke, Kenneth R.
Afiliação
  • Artz AS; Section of Hematology/Oncology, University of Chicago School of Medicine, IL, USA aartz@medicine.bsd.uchicago.edu.
  • Logan B; CIBMTR, (Center for International Blood and Marrow Transplant Research), Department of Medicine, Milwaukee, WI, USA.
  • Zhu X; Division of Biostatistics, Institute for Health and Society, Medical College of Wisconsin, Milwaukee, WI, USA.
  • Akpek G; CIBMTR, (Center for International Blood and Marrow Transplant Research), Department of Medicine, Milwaukee, WI, USA.
  • Bufarull RM; Stem Cell Transplantation and Cellular Therapy Program, Banner MD Anderson Cancer Center, Gilbert, AZ, USA.
  • Gupta V; Division of Clinical Hematology, Hospital de la Santa Creu I Sant Pau, Barcelona, Spain.
  • Lazarus HM; Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, Canada.
  • Litzow M; Seidman Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA.
  • Loren A; Division of Hematology and Transplant Center, Mayo Clinic Rochester, Minneapolis, MN, USA.
  • Majhail NS; Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA.
  • Maziarz RT; Blood & Marrow Transplant Program, Cleveland Clinic Taussig Cancer Institute, OH, USA.
  • McCarthy P; Adult Blood and Marrow Stem Cell Transplant Program, Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA.
  • Popat U; Blood & Marrow Transplant Program, Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY, USA.
  • Saber W; MD Anderson Cancer Center, Houston, TX, USA.
  • Spellman S; CIBMTR, (Center for International Blood and Marrow Transplant Research), Department of Medicine, Milwaukee, WI, USA.
  • Ringden O; CIBMTR (Center for International Blood and Marrow Transplant Research), National Marrow Donor Program/Be The Match, Minneapolis, MN, USA.
  • Wickrema A; Division of Therapeutic Immunology, Department of Laboratory Medicine, Karolinska Institute, Stockholm, Sweden.
  • Pasquini MC; Centre for Allogeneic Stem Cell Transplantation, Stockholm, Sweden.
  • Cooke KR; Section of Hematology/Oncology, University of Chicago School of Medicine, IL, USA.
Haematologica ; 101(11): 1426-1433, 2016 11.
Article em En | MEDLINE | ID: mdl-27662010
ABSTRACT
We sought to confirm the prognostic importance of simple clinically available biomarkers of C-reactive protein, serum albumin, and ferritin prior to allogeneic hematopoietic cell transplantation. The study population consisted of 784 adults with acute myeloid leukemia in remission or myelodysplastic syndromes undergoing unrelated donor transplant reported to the Center for International Blood and Marrow Transplant Research. C-reactive protein and ferritin were centrally quantified by ELISA from cryopreserved plasma whereas each center provided pre-transplant albumin. In multivariate analysis, transplant-related mortality was associated with the pre-specified thresholds of C-reactive protein more than 10 mg/L (P=0.008) and albumin less than 3.5 g/dL (P=0.01) but not ferritin more than 2500 ng/mL. Only low albumin independently influenced overall mortality. Optimal thresholds affecting transplant-related mortality were defined as C-reactive protein more than 3.67 mg/L, log(ferritin), and albumin less than 3.4 g/dL. A 3-level biomarker risk group based on these values separated risks of transplant-related mortality low risk (reference), intermediate (HR=1.66, P=0.015), and high risk (HR=2.7, P<0.001). One-year survival was 74%, 67% and 56% for low-, intermediate- and high-risk groups. Routinely available pre-transplant biomarkers independently risk-stratify for transplant-related mortality and survival.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Proteína C-Reativa / Albumina Sérica / Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas / Ferritinas Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndromes Mielodisplásicas / Proteína C-Reativa / Albumina Sérica / Leucemia Mieloide Aguda / Transplante de Células-Tronco Hematopoéticas / Ferritinas Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged Idioma: En Ano de publicação: 2016 Tipo de documento: Article